269 related articles for article (PubMed ID: 16865780)
21. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
Deushi M; Nomura M; Kawakami A; Haraguchi M; Ito M; Okazaki M; Ishii H; Yoshida M
FEBS Lett; 2007 Dec; 581(29):5664-70. PubMed ID: 18022391
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of hepatic interleukin-18 production by rosiglitazone in a rat model of nonalcoholic fatty liver disease.
Wang HN; Wang YR; Liu GQ; Liu Z; Wu PX; Wei XL; Hong TP
World J Gastroenterol; 2008 Dec; 14(47):7240-6. PubMed ID: 19084941
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease.
Ganji SH; Kukes GD; Lambrecht N; Kashyap ML; Kamanna VS
Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G320-7. PubMed ID: 24356885
[TBL] [Abstract][Full Text] [Related]
24. Ezetimibe prevents hepatic steatosis induced by a high-fat but not a high-fructose diet.
Ushio M; Nishio Y; Sekine O; Nagai Y; Maeno Y; Ugi S; Yoshizaki T; Morino K; Kume S; Kashiwagi A; Maegawa H
Am J Physiol Endocrinol Metab; 2013 Jul; 305(2):E293-304. PubMed ID: 23715726
[TBL] [Abstract][Full Text] [Related]
25. [Effects of rosiglitazone and metformin on insulin resistance in high-fat diet rats].
Chen XP; Yang WY; Bu S; Xiao JZ; Liu XL; Wang N; Zhao WH
Zhonghua Nei Ke Za Zhi; 2004 Apr; 43(4):280-3. PubMed ID: 15130413
[TBL] [Abstract][Full Text] [Related]
26. Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis.
Kitamura K; Tada S; Nakamoto N; Toda K; Horikawa H; Kurita S; Tsunematsu S; Kumagai N; Ishii H; Saito H; Hibi T
J Gastroenterol Hepatol; 2007 Nov; 22(11):2022-33. PubMed ID: 17914985
[TBL] [Abstract][Full Text] [Related]
27. [The effects of renin-angiotensin system blockade on the liver steatosis in rats on long-term high-fat diet].
Chen YH; Yuan L; Chen YY; Qi CJ
Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):197-201. PubMed ID: 18785501
[TBL] [Abstract][Full Text] [Related]
28. [Effect of high-fat diet, rosiglitazone on lipid profile, insulin resistance and liver steatosis development].
Tacikowski T; Nowicka G; Bujko J; Walewska-Zielecka B; Dzieniszewski J
Pol Arch Med Wewn; 2005 Mar; 113(3):213-22. PubMed ID: 16128278
[TBL] [Abstract][Full Text] [Related]
29. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
[TBL] [Abstract][Full Text] [Related]
30. Combination of vildagliptin and rosiglitazone ameliorates nonalcoholic fatty liver disease in C57BL/6 mice.
Mookkan J; De S; Shetty P; Kulkarni NM; Devisingh V; Jaji MS; Lakshmi VP; Chaudhary S; Kulathingal J; Rajesh NB; Narayanan S
Indian J Pharmacol; 2014; 46(1):46-50. PubMed ID: 24550584
[TBL] [Abstract][Full Text] [Related]
31. Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway.
Zhang W; Wu R; Zhang F; Xu Y; Liu B; Yang Y; Zhou H; Wang L; Wan K; Xiao X; Zhang X
Clin Exp Pharmacol Physiol; 2012 Dec; 39(12):1026-33. PubMed ID: 23127227
[TBL] [Abstract][Full Text] [Related]
32. [Effects of glucagon-like peptide-1 on liver oxidative stress, TNF-α and TGF-β1 in rats with non-alcoholic fatty liver disease].
Gao H; Xu L; Li D; Guang L; Deng W
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Nov; 33(11):1661-4. PubMed ID: 24273273
[TBL] [Abstract][Full Text] [Related]
33. Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice.
Liu LF; Purushotham A; Wendel AA; Belury MA
Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1671-82. PubMed ID: 17322064
[TBL] [Abstract][Full Text] [Related]
34. Paraoxonase activity and expression is modulated by therapeutics in experimental rat nonalcoholic Fatty liver disease.
Hussein O; Zidan J; Abu Jabal K; Shams I; Szvalb S; Grozovski M; Bersudsky I; Karry R; Aviram M
Int J Hepatol; 2012; 2012():265305. PubMed ID: 22536512
[TBL] [Abstract][Full Text] [Related]
35. Schisandra chinensis Baill, a Chinese medicinal herb, alleviates high-fat-diet-inducing non-alcoholic steatohepatitis in rats.
Yao Z; Liu XC; Gu YE
Afr J Tradit Complement Altern Med; 2014; 11(1):222-7. PubMed ID: 24653581
[TBL] [Abstract][Full Text] [Related]
36. Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin.
Ye JM; Dzamko N; Cleasby ME; Hegarty BD; Furler SM; Cooney GJ; Kraegen EW
Diabetologia; 2004 Jul; 47(7):1306-1313. PubMed ID: 15232684
[TBL] [Abstract][Full Text] [Related]
37. [Effect of total alkaloids of Rubus alceaefolius on oxidative stress in rats with non-alcoholic fatty liver disease].
Zheng H; Zhao J; Liu Y; Zheng Y; Wu J; Hong Z
Zhongguo Zhong Yao Za Zhi; 2011 Sep; 36(17):2383-7. PubMed ID: 22121808
[TBL] [Abstract][Full Text] [Related]
38. Novel role of NPC1L1 in the regulation of hepatic metabolism: potential contribution of ezetimibe in NAFLD/NASH treatment.
Yoshida M
Curr Vasc Pharmacol; 2011 Jan; 9(1):121-3. PubMed ID: 21044016
[TBL] [Abstract][Full Text] [Related]
39. [Study on therapeutic effects of metformin on rat fatty livers induced by high fat feeding].
Gao ZQ; Lu FE; Dong H; Xu LJ; Wang KF; Zhou X
Zhonghua Gan Zang Bing Za Zhi; 2005 Feb; 13(2):101-4. PubMed ID: 15727694
[TBL] [Abstract][Full Text] [Related]
40. Rosiglitazone and bezafibrate modulate gene expression in a rat model of non-alcoholic fatty liver disease--a historical prospective.
Schmilovitz-Weiss H; Hochhauser E; Cohen M; Chepurko Y; Yitzhaki S; Grossman E; Leibowitz A; Ackerman Z; Ben-Ari Z
Lipids Health Dis; 2013 Mar; 12():41. PubMed ID: 23531105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
